AXSM
HealthcareAxsome Therapeutics, Inc. · Biotechnology · $12B
What is Axsome Therapeutics, Inc.?
Axsome Therapeutics is a biopharmaceutical company focused on developing novel treatments for central nervous system disorders. Headquartered in New York City, it was incorporated in 2012.
Axsome advances a pipeline of investigational medicines targeting CNS conditions including major depressive disorder, migraine, narcolepsy, and fibromyalgia. The company generates revenue through commercialized therapies while continuing to fund late-stage clinical trials across its pipeline, with a research collaboration with Duke University for smoking cessation.
Axsome Therapeutics was founded in 2015 and is based in New York City, New York.
- AXS-05 — treatment for major depressive disorder and Alzheimer's disease agitation
- AXS-07 — investigational oral therapy for acute migraine
- AXS-12 — norepinephrine reuptake inhibitor for narcolepsy
- AXS-14 — investigational oral medicine for fibromyalgia
Is AXSM a Good Stock to Buy?
UQS Score rates AXSM as Below Average overall.
Growth stands out as the strongest pillar, reflecting the company's expanding CNS pipeline and commercial momentum. Valuation is rated Good relative to sector peers, suggesting the market has not yet priced in an outsized premium.
Quality, Moat, and Risk all register as Weak, pointing to the financial and competitive challenges common to clinical-stage biopharmaceutical companies.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does AXSM pay dividends?
No — Axsome Therapeutics, Inc. does not currently pay a dividend.
Axsome Therapeutics does not pay a dividend. As a clinical-stage biopharmaceutical company, available capital is directed toward advancing its CNS drug pipeline through costly late-stage trials rather than returning cash to shareholders.
When does AXSM report earnings?
Axsome Therapeutics reports earnings on a quarterly cadence, typical for US-listed equities.
Results in recent quarters have reflected the dual pressures of growing commercial revenues and ongoing pipeline investment. Spending on clinical trials continues to weigh on near-term profitability, a pattern common among biopharmaceutical companies at this stage.
For the most recent quarter's results, visit Axsome Therapeutics' investor relations page.
AXSM Price History
+201.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Axsome Therapeutics, Inc.?
Based on Axsome Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Axsome Therapeutics do?
Axsome Therapeutics develops novel medicines for central nervous system disorders. Its pipeline targets conditions including major depressive disorder, migraine, narcolepsy, fibromyalgia, and Alzheimer's disease agitation, with several candidates in Phase III clinical trials.
Does AXSM pay dividends?
No, AXSM does not currently pay a dividend. The company reinvests available capital into its clinical pipeline rather than distributing cash to shareholders, which is typical for biopharmaceutical companies at this stage of development.
When does AXSM report earnings?
Axsome Therapeutics reports on a standard quarterly cadence. Our data source does not cover specific upcoming dates, so check the company's investor relations page for the most current earnings schedule.
Is AXSM a good stock to buy?
UQS Score rates AXSM as Below Average overall. Growth is a standout strength, but Weak ratings across Quality, Moat, and Risk reflect meaningful challenges. The complete pillar breakdown is available to Pro members.
Is AXSM overvalued?
The UQS Valuation pillar for AXSM is rated Good, suggesting the stock is not significantly overpriced relative to sector peers at current levels. View the full valuation analysis by signing up for UQS Pro.
What is AXSM's market cap bracket?
Axsome Therapeutics is classified as a mid-cap company, placing it between smaller clinical-stage biotechs and larger established pharmaceutical firms in terms of market size.
Is AXSM a long-term quality investment?
Long-term quality indicators for AXSM are mixed. The Strong Growth pillar signals pipeline potential, but Weak Quality, Moat, and Risk ratings highlight the execution and financial risks inherent to CNS drug development. Pro members can access the full long-term quality view.
What sector does AXSM belong to?
Axsome Therapeutics operates in the Healthcare sector, specifically within biopharmaceuticals. It focuses exclusively on central nervous system disorders, a specialized and competitive therapeutic area.
Unlock Full AXSM Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access detailed financial metrics and trend data
- ✓Compare AXSM against CNS and biopharmaceutical peers
- ✓Get the complete analyst-style breakdown in one place
Pro Analysis
AXSM — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 46.3 | 16.7 | 34.0 | 100.0 | 31.8 | 58.8 | 0.0 |
| May 22, 2026 | 46.3 | 16.7 | 34.0 | 100.0 | 31.8 | 58.9 | 0.0 |
| May 21, 2026 | 46.3 | 16.7 | 34.0 | 100.0 | 31.8 | 59.1 | 0.0 |
| May 20, 2026 | 46.3 | 16.7 | 34.0 | 100.0 | 31.8 | 59.4 | 0.0 |
| May 16, 2026 | 46.3 | 16.7 | 34.0 | 100.0 | 31.8 | 59.3 | 0.0 |
| May 15, 2026 | 46.3 | 16.7 | 34.0 | 100.0 | 31.8 | 59.0 | 0.0 |
| May 14, 2026 | 46.3 | 16.7 | 34.0 | 100.0 | 31.8 | 58.8 | -0.1 |
| May 13, 2026 | 46.4 | 16.7 | 34.0 | 100.0 | 31.8 | 59.5 | 0.0 |
| May 12, 2026 | 46.4 | 16.7 | 34.0 | 100.0 | 31.8 | 60.0 | 0.0 |
| May 11, 2026 | 46.4 | 16.7 | 34.0 | 100.0 | 31.8 | 59.7 | +4.2 |
AXSM — Pillar Breakdown
Quality
— 16.7/100 (25%)Axsome Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)Axsome Therapeutics, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 31.8/100 (15%)Axsome Therapeutics, Inc. presents elevated risk with concerns around leverage or financial stability.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 58.8/100 (15%)Axsome Therapeutics, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 34/100 (25%)Axsome Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for AXSM.
Score Composition
Financial Data
More Stock Analysis
How is the AXSM UQS Score Calculated?
The UQS (Unified Quality Score) for Axsome Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Axsome Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Axsome Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.